For example, in preclinical studies, pH‐responsive exosome‐nanocouples have been developed by modifying the surface of M1 macrophage‐secreted exosomes with anti‐CD47 and anti‐SIRPα antibodies through acid‐cleavable of dibenzoylethylene bonds, targeting tumor cells. This evidence concerns the gene SIRPA and neoplasm.